Analiza skuteczności ibrutynibu w podgrupie chorych na przewlekłą białaczkę limfocytową z delecją 17p: badanie obserwacyjne Polskiej Grupy ds. Leczenia Białaczek u Dorosłych (PALG)

• Published in: Acta haematologica polonica Vol. 48; no. 4; pp. 330 - 337
• Main Authors: Puła, Bartosz, Iskierka-Jażdżewska, Elżbieta, Hus, Marek, Szymczyk, Agnieszka, Gołos, Aleksandra, Piotrowska, Magdalena, Zawirska, Daria, Zaucha, Jan Maciej, Steckiewicz, Paweł, Pasiarski, Marcin, Chraniuk, Dominik, Piszczek, Weronika, Osowiecki, Michał, Subocz, Edyta, Hałka, Janusz, Waszczuk-Gajda, Anna, Drozd-Sokołowska, Joanna, Knopińska-Posłuszny, Wanda, Dudziński, Marek, Hołojda, Jadwiga, Wojciechowska, Małgorzata, Kulikowski, Waldemar, Szeremet, Agnieszka, Kumiega, Beata, Pluta, Andrzej, Markiewicz, Mirosław, Giannopoulos, Krzysztof, Robak, Tadeusz, Warzocha, Krzysztof, Jamroziak, Krzysztof
• Format: Journal Article
• Language: Polish
• Published: Elsevier Urban & Partner Sp. z o.o 01.10.2017
• Subjects: 17p deletion; BTK inhibitor; chronic lymphocytic leukemia; delecja 17p; ibrutinib; ibrutynib; inhibitor BTK; przewlekła białaczka limfocytowa; ibrutinib; przewlekła białaczka limfocytowa; chronic lymphocytic leukemia; inhibitor BTK; 17p deletion; ibrutynib; BTK inhibitor; delecja 17p
• ISSN: 0001-5814
• DOI: 10.1016/j.achaem.2017.10.004

The 17p deletion is regarded as the strongest poor prognostic factor in chronic lymphocytic leukemia (CLL). Results of recently performed clinical trials have suggested that ibrutinib significantly improves the outcome in this patient group. The study aimed at analyzing the efficacy and adverse events profile of ibrutinib monotherapy in CLL patients with 17p deletion treated in routine clinical practice outside clinical trials. Clinical response and adverse events profile of ibrutinib monotherapy were assessed in thirty-five CLL patients with 17p deletion treated within the ibrutinib named patients program in Poland. Overall response rate was 80% (28/35 patients) with median observation time of 24.2 months (range 0,1 – 30,9). Complete remission was observed in 5 patients (14.3%), partial remission in 11 (31.4%), partial remission with lymphocytosis in 13 (37.1%), whereas stable disease and progression was noted in 4 (11.4%) and 1 (2.9%) respectively. Response was not assessed in 1 patient. Median progression-free survival was 29.5 months, whereas median overall survival was not reached. Eleven patients died (7 because of infection, 1 of CLL progression, 1 of sudden cardiac death, 1 of disseminated breast cancer and 1 of unknown causes). In 13 patients (37.1%) at least one 3 or 4 grade adverse event occurred. In 11 patients (31.4%) the treatment was temporary withheld or the dose reduced due to adverse events. Ibrutinib is characterized by high clinical efficacy and acceptable toxicity in CLL patients with 17p deletion in daily clinical practice.